BACKGROUND: The incidence, dynamics, and management of cytopenias were investigated in patients with chronic myeloid leukemia in chronic phase (CP CML) who received dasatinib therapy after imatinib failure. METHODS: Data were analyzed from 130 patients with CP CML who were treated with dasatinib from November 2003 to March 2006 in phase 1 (n = 22) or phase 2 or 3 (n = 108) studies for the development of grade 2 to 4 cytopenia (according to the National Cancer Institute Common Terminology Criteria [version 3.0]). RESULTS: Grade 2 to 4 neutropenia and/or thrombocytopenia occurred in 94 (72%) patients during dasatinib therapy and grade 3 to 4 occurred in 67 (52%) patients. Of the 94 patients who developed grade 2 to 4 neutropenia and/or thrombocytopenia, 64 (68%) also developed at least grade 2 anemia, and 16 (17%) developed grade 3 to 4 anemia. Management of cytopenias included transient dasatinib interruption in 35 (37%) patients, filgrastim in 12 (14%) patients, recombinant erythropoietin in 29 (45%) patients, and interleukin-11 in 3 (5%) patients. Factors associated with an increased risk for developing grade 2 to 4 cytopenias were longer time from diagnosis to treatment, prior interferon or imatinib therapy, and a lower white blood cell count at the initiation of dasatinib therapy. CONCLUSIONS: Hematologic toxicity was frequent during dasatinib therapy in patients with CP CML, particularly at doses >100 mg daily. Treatment interruption and/or dose reduction as well as growth factor support were found to be safe and efficacious strategies to facilitate the continuous administration of dasatinib.
BACKGROUND: The incidence, dynamics, and management of cytopenias were investigated in patients with chronic myeloid leukemia in chronic phase (CP CML) who received dasatinib therapy after imatinib failure. METHODS: Data were analyzed from 130 patients with CP CML who were treated with dasatinib from November 2003 to March 2006 in phase 1 (n = 22) or phase 2 or 3 (n = 108) studies for the development of grade 2 to 4 cytopenia (according to the National Cancer Institute Common Terminology Criteria [version 3.0]). RESULTS: Grade 2 to 4 neutropenia and/or thrombocytopenia occurred in 94 (72%) patients during dasatinib therapy and grade 3 to 4 occurred in 67 (52%) patients. Of the 94 patients who developed grade 2 to 4 neutropenia and/or thrombocytopenia, 64 (68%) also developed at least grade 2 anemia, and 16 (17%) developed grade 3 to 4 anemia. Management of cytopenias included transient dasatinib interruption in 35 (37%) patients, filgrastim in 12 (14%) patients, recombinant erythropoietin in 29 (45%) patients, and interleukin-11 in 3 (5%) patients. Factors associated with an increased risk for developing grade 2 to 4 cytopenias were longer time from diagnosis to treatment, prior interferon or imatinib therapy, and a lower white blood cell count at the initiation of dasatinib therapy. CONCLUSIONS:Hematologic toxicity was frequent during dasatinib therapy in patients with CP CML, particularly at doses >100 mg daily. Treatment interruption and/or dose reduction as well as growth factor support were found to be safe and efficacious strategies to facilitate the continuous administration of dasatinib.
Authors: Louis J Lombardo; Francis Y Lee; Ping Chen; Derek Norris; Joel C Barrish; Kamelia Behnia; Stephen Castaneda; Lyndon A M Cornelius; Jagabandhu Das; Arthur M Doweyko; Craig Fairchild; John T Hunt; Ivan Inigo; Kathy Johnston; Amrita Kamath; David Kan; Herbert Klei; Punit Marathe; Suhong Pang; Russell Peterson; Sidney Pitt; Gary L Schieven; Robert J Schmidt; John Tokarski; Mei-Li Wen; John Wityak; Robert M Borzilleri Journal: J Med Chem Date: 2004-12-30 Impact factor: 7.446
Authors: J E Godwin; K J Kopecky; D R Head; C L Willman; C P Leith; H E Hynes; S P Balcerzak; F R Appelbaum Journal: Blood Date: 1998-05-15 Impact factor: 22.113
Authors: Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers Journal: N Engl J Med Date: 2006-06-15 Impact factor: 91.245
Authors: Alfonso Quintas-Cardama; Hagop Kantarjian; Susan O'Brien; Guillermo Garcia-Manero; Mary B Rios; Moshe Talpaz; Jorge Cortes Journal: Cancer Date: 2004-06-15 Impact factor: 6.860
Authors: D Marin; S Marktel; M Bua; R M Szydlo; A Franceschino; I Nathan; N Foot; C Crawley; T Na Nakorn; E Olavarria; A Lennard; A Neylon; S G O'Brien; J M Goldman; J F Apperley Journal: Leukemia Date: 2003-08 Impact factor: 11.528
Authors: Thomas B Sneed; Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rios; B Nebiyou Bekele; Xian Zhou; Debra Resta; William Wierda; Stefan Faderl; Francis Giles; Jorge E Cortes Journal: Cancer Date: 2004-01-01 Impact factor: 6.860
Authors: Jorge Cortes; Susan O'Brien; Alfonso Quintas; Francis Giles; Jianquin Shan; Mary Beth Rios; Moshe Talpaz; Hagop Kantarjian Journal: Cancer Date: 2004-06-01 Impact factor: 6.860
Authors: Hanna L M Rajala; Mohamed El Missiry; Anniina Ruusila; Perttu Koskenvesa; Tim H Brümmendorf; Bjorn T Gjertsen; Jeroen Janssen; Kourosh Lotfi; Berit Markevärn; Ulla Olsson-Strömberg; Leif Stenke; Jesper Stentoft; Johan Richter; Henrik Hjorth-Hansen; Anna Kreutzman; Satu Mustjoki Journal: J Cancer Res Clin Oncol Date: 2017-03-23 Impact factor: 4.553
Authors: W Andrew Owens; Anna Walaszczyk; Ioakim Spyridopoulos; Emily Dookun; Gavin D Richardson Journal: Mech Ageing Dev Date: 2021-07-06 Impact factor: 5.432